Skip to main content

Table 2 General characteristics in control, diabetic, and diabetic treated with low and high doses of exenatide

From: Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats

 

C

D

DTL

DTH

Number

7

10

10

9

Plasma glucose (mM)

4.31 ± 0.72

29.86 ± 1.32*

29.08 ± 1.20*

28.66 ± 0.89*

Plasma Insulin (Iu/ml)

19.36 ± 0.58

4.91 ± 0.27*

5.06 ± 0.30*

5.19 ± 0.31*

Plasma total cholesterol (mM )

1.46 ± 0.38

2.79 ± 0.29*

2.77 ± 0.50*

2.27 ± 0.72a*,#

Plasma triglycerides (mM )

0.83 ± 0.13

1.42 ± 0.20*

1.29 ± 0.27*

1.08 ± 0.87#

Plasma free fatty acid (mM )

1.45 ± 0.20

2.60 ± 0.41*

2.26 ± 0.63*

1.53 ± 0.34#,$

Body weight (g)

459.57 ± 86.52

207.70 ± 48.89*

200.60 ± 74.48*

211.11 ± 41.20*

Heart weight (g)

1.30 ± 0.17

0.93 ± 0.29*

0.85 ± 0.20*

0.88 ± 0.23*

Heart/body weight (g/kg)

2.86 ± 0.38

4.50 ± 0.68*

4.42 ± 0.76*

4.42 ± 0.86*

  1. Values were obtained at sacrifice, after administration with or without 8 weeks of exenatide treatment. Control (C), diabetic (D), diabetic treated with low dose (2 μg · kg−1.d−1) of exenatide (DTL), diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide (DTH). All values were expressed as mean ± S.E.M. *P < 0.05 or 0.01 vs. C; #P < 0.05 vs. D; $P < 0.05 vs. DTL.